Physician profile
Michael Bourne
NPI 1881030443
$6,335.35
in general payments reported to CMS, 2019-2025
17 companies · $703 in 2025
The $703 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2022: $22.43 · 2024: $5,475 · 2025: $703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,500 · Travel and Lodging: $2,073 · Food and Beverage: $1,605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,500.00 |
| Travel and Lodging | $2,072.97 |
| Food and Beverage | $1,605.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,085.40 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $276.36 | 2024-2025 | Fasenra, Airsupra, Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $195.43 | 2024-2025 | Glassia |
| Pulmonx Corporation | $137.38 | 2024-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Grifols USA, LLC | $105.00 | 2024-2025 | Prolastin-C Liquid |
| Insmed, INC. | $76.61 | 2024-2025 | Arikayce, Brinsupri |
| Baxter Healthcare | $65.47 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Regeneron Healthcare Solutions, INC. | $64.85 | 2025 | Dupixent |
| Merck Sharp & Dohme LLC | $58.00 | 2025 | Winrevair |
| Scpharmaceuticals INC. | $54.70 | 2024 | |
| Viatris Specialty LLC | $50.41 | 2025 | Yupelri |
| Verona Pharma, INC. | $45.60 | 2025 | Ohtuvayre |
| Procyrion, INC. | $32.94 | 2024 | |
| United Therapeutics Corporation | $32.20 | 2025 | Tyvaso |
| Ani Pharmaceuticals, INC. | $21.36 | 2024 | Purified Cortrophin Gel |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $19.59 | 2024 | Tezspire |
| Novartis Pharmaceuticals Corporation | $14.05 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bourne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.